ATAI Investor Presentation Deck
We will build on recent success by delivering several meaningful R&D catalysts
anticipated across our key programs in 2022, 2023 & 2024
Milestone highlights in 2021
Positive topline results in Phase 2b trial of
COMP360 in TRD patients
Successful outcomes of Phase 2a proof-of-
mechanism trial of RL-007 in CIAS patients
Successful outcomes of Phase 1 trial of PCN-
101 (R-ketamine) in healthy volunteers
Collaboration agreement with Otsuka
Pharma on development of PCN-101 (R-
ketamine) in Japan
Acquired or incubated 6 new platform
companies (expanding to a total of 18
affiliates)
Anticipated catalysts across 2022, 2023 & 2024
H2
2022
H1
2022
COMP360
Psilocybin end
of Ph2 meeting
with FDA
PCN-101/R-
ketamine Ph.2a
results
PCN-101/R-
ketamine DDI
results
COMP360/
Psilocybin Ph.3
initiation
GRX-917/Deuterated
etifoxine Ph.1 results
DMX-1002/lbogaine
Ph.1 results
KUR-101 / Deuterated
mitragynine Ph.1
results.
H1
2023
VLS-01/DMT
Ph.1 results
H2
2023
EMP-01/
MDMA
derivative Ph.1
results
H1
2024
RL-007
Ph.2b proof-
of-concept
results
08.View entire presentation